Analyst Research and Ratings: FireEye, Inc. (FEYE), Immunomedics, Inc. (IMMU)

FireEye, Inc. (NASDAQ:FEYE) tinted gains of +2.62% (+0.45 points) to US$17.65. The volume of 3.31 Million shares climbed down over an trading activity of 5.16 Million shares. EPS ratio determined by looking at last 12 month figures is -1.45. Over the same time span, the stock marked US$20.61 as its best level and the lowest price reached was US$13.6. The corporation has a market cap of US$3.42 Billion.

FireEye, Inc. (NASDAQ:FEYE)’s earnings per share has been growing at a 12.2 percent rate over the past 5 year when average revenue increase was noted as 55.2 percent. The return on equity ratio or ROE stands at -42.4 percent while most common profitability ratio return on investment (ROI) was -18.6 percent. The company’s institutional ownership is monitored at 77.2 percent. The company’s net profit margin has achieved the current level of -33.3 percent and possesses 66.7 percent gross margin.

Daily Analyst Recommendations

A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 7 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 13 think it is Hold. Recently, analysts have updated the overall rating to 2.3. 6 analysts recommended Overweight these shares while 1 recommended Underweight, according to FactSet data.

Immunomedics, Inc. (NASDAQ:IMMU) is worth US$3.76 Billion and has recently risen 2.61% to US$14.53. The latest exchange of 3.93 Million shares is above its average trading activity of 3.27 Million shares. The day began at US$14.3 but the price moved to US$13.83 at one point during the trading and finally capitulating to a session high of US$14.51. The stock tapped a 52-week high of US$27.33 while the mean 12-month price target for the shares is US$37.38.

Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 7.9, and a price to sales ratio of 2507.01. For the past 5 years, the company’s revenue has grown -15.4%, while the company’s earnings per share has grown -65%. With an institutional ownership near 79.7%, it carries an earnings per share ratio of -1.23.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 2 brokerage firms polled by Factset Research. At present, 2 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 4 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.